Achilles Therapeutics Ownership 2024 | Who Owns Achilles Therapeutics Now?
Institutional Ownership
38.91%
Insider Ownership
6.51%
Retail Ownership
54.57%
Institutional Holders
14.00
Achilles Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 27.59% | 9.24% | 11,086,909 | - | - | 13,858,636 | Mar 31, 2024 |
| FCPM III SERVICES B.V. | 5.95% | 0.42% | 2,390,050 | - | - | 2,987,563 | Mar 31, 2024 |
| REDMILE GROUP, LLC | 4.00% | 0.07% | 1,608,089 | - | - | 2,010,111 | Mar 31, 2024 |
| VESTAL POINT CAPITAL, LP | 3.73% | 0.16% | 1,500,000 | 1,391,917 | 1287.82% | 1,875,000 | Mar 31, 2024 |
| IKARIAN CAPITAL, LLC | 3.59% | 0.20% | 1,443,181 | 1,443,181 | 100.00% | 1,803,976 | Mar 31, 2024 |
| STEMPOINT CAPITAL LP | 3.45% | 0.46% | 1,385,750 | 1,385,750 | 100.00% | 1,732,188 | Mar 31, 2024 |
| BAKER BROS. ADVISORS LP | 3.01% | 0.02% | 1,208,775 | -894,017 | -42.52% | 1,510,969 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 2.50% | 0.00% | 1,005,759 | 506,764 | 101.56% | 1,257,000 | Mar 31, 2024 |
| ARTAL GROUP S.A. | 1.88% | 0.02% | 755,375 | -1,500,000 | -66.51% | 944,219 | Mar 31, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.05% | 0.01% | 420,481 | 420,481 | 100.00% | 525,601 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.70% | 0.00% | 280,929 | 280,929 | 100.00% | 350,000 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.26% | - | 104,993 | -3,461 | -3.19% | 131,241 | Mar 31, 2024 |
| FOREFRONT ANALYTICS, LLC | 0.24% | 0.06% | 95,445 | 19,176 | 25.14% | 119,310 | Mar 31, 2024 |
| HRT FINANCIAL LP | 0.09% | 0.00% | 36,918 | 36,918 | 100.00% | 46,000 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.05% | - | 21,590 | - | - | 26,987 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.05% | - | 19,117 | -11,832 | -38.23% | 23,896 | Mar 31, 2024 |
| VONTOBEL HOLDING LTD. | 0.05% | 0.00% | 19,000 | 19,000 | 100.00% | 23,750 | Mar 31, 2024 |
| MORGAN STANLEY | 0.05% | - | 18,201 | 18,181 | 90905.00% | 22,751 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 0.04% | 0.00% | 17,900 | 17,900 | 100.00% | 22,375 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.04% | 0.00% | 16,312 | 1,773 | 12.19% | 20,390 | Mar 31, 2024 |
Achilles Therapeutics's largest institutional shareholder is SYNCONA PORTFOLIO LTD, holding 27.59% of the company's total share outstanding, currently valued at $13.86M. The top 10 institutional shareholders own together 56.75% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 27.59% | 9.24% | 11,086,909 | - | - | 13,858,636 | Mar 31, 2024 |
| STEMPOINT CAPITAL LP | 3.45% | 0.46% | 1,385,750 | 1,385,750 | 100.00% | 1,732,188 | Mar 31, 2024 |
| FCPM III SERVICES B.V. | 5.95% | 0.42% | 2,390,050 | - | - | 2,987,563 | Mar 31, 2024 |
| IKARIAN CAPITAL, LLC | 3.59% | 0.20% | 1,443,181 | 1,443,181 | 100.00% | 1,803,976 | Mar 31, 2024 |
| VESTAL POINT CAPITAL, LP | 3.73% | 0.16% | 1,500,000 | 1,391,917 | 1287.82% | 1,875,000 | Mar 31, 2024 |
| REDMILE GROUP, LLC | 4.00% | 0.07% | 1,608,089 | - | - | 2,010,111 | Mar 31, 2024 |
| FOREFRONT ANALYTICS, LLC | 0.24% | 0.06% | 95,445 | 19,176 | 25.14% | 119,310 | Mar 31, 2024 |
| ARTAL GROUP S.A. | 1.88% | 0.02% | 755,375 | -1,500,000 | -66.51% | 944,219 | Mar 31, 2024 |
| BAKER BROS. ADVISORS LP | 3.01% | 0.02% | 1,208,775 | -894,017 | -42.52% | 1,510,969 | Mar 31, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.05% | 0.01% | 420,481 | 420,481 | 100.00% | 525,601 | Mar 31, 2024 |
| BRAVE ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,000 | 10,000 | 100.00% | 12,500 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.04% | 0.00% | 15,219 | 15,219 | 100.00% | 19,024 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 2.50% | 0.00% | 1,005,759 | 506,764 | 101.56% | 1,257,000 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.70% | 0.00% | 280,929 | 280,929 | 100.00% | 350,000 | Mar 31, 2024 |
| HRT FINANCIAL LP | 0.09% | 0.00% | 36,918 | 36,918 | 100.00% | 46,000 | Mar 31, 2024 |
| RESOURCES INVESTMENT ADVISORS, LLC. | 0.03% | 0.00% | 10,500 | 10,500 | 100.00% | 13,125 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.04% | 0.00% | 16,312 | 1,773 | 12.19% | 20,390 | Mar 31, 2024 |
| VONTOBEL HOLDING LTD. | 0.05% | 0.00% | 19,000 | 19,000 | 100.00% | 23,750 | Mar 31, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 400 | 400 | 100.00% | 500 | Mar 31, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.01% | 0.00% | 2,000 | -1,000 | -33.33% | 2,500,000 | Mar 31, 2024 |
The largest Achilles Therapeutics shareholder by % of total assets is SYNCONA PORTFOLIO LTD. The company owns 11.09M shares of Achilles Therapeutics (ACHL), representing 9.24% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IKARIAN CAPITAL, LLC | 3.59% | 0.20% | 1,443,181 | 1,443,181 | 100.00% | 1,803,976 | Mar 31, 2024 |
| VESTAL POINT CAPITAL, LP | 3.73% | 0.16% | 1,500,000 | 1,391,917 | 1287.82% | 1,875,000 | Mar 31, 2024 |
| STEMPOINT CAPITAL LP | 3.45% | 0.46% | 1,385,750 | 1,385,750 | 100.00% | 1,732,188 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 2.50% | 0.00% | 1,005,759 | 506,764 | 101.56% | 1,257,000 | Mar 31, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.05% | 0.01% | 420,481 | 420,481 | 100.00% | 525,601 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.70% | 0.00% | 280,929 | 280,929 | 100.00% | 350,000 | Mar 31, 2024 |
| HRT FINANCIAL LP | 0.09% | 0.00% | 36,918 | 36,918 | 100.00% | 46,000 | Mar 31, 2024 |
| FOREFRONT ANALYTICS, LLC | 0.24% | 0.06% | 95,445 | 19,176 | 25.14% | 119,310 | Mar 31, 2024 |
| VONTOBEL HOLDING LTD. | 0.05% | 0.00% | 19,000 | 19,000 | 100.00% | 23,750 | Mar 31, 2024 |
| MORGAN STANLEY | 0.05% | - | 18,201 | 18,181 | 90905.00% | 22,751 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 0.04% | 0.00% | 17,900 | 17,900 | 100.00% | 22,375 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.04% | 0.00% | 15,219 | 15,219 | 100.00% | 19,024 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.03% | - | 11,799 | 11,799 | 100.00% | 14,749 | Mar 31, 2024 |
| RESOURCES INVESTMENT ADVISORS, LLC. | 0.03% | 0.00% | 10,500 | 10,500 | 100.00% | 13,125 | Mar 31, 2024 |
| BRAVE ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,000 | 10,000 | 100.00% | 12,500 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | 0.01% | - | 3,514 | 3,514 | 100.00% | 4,391,000 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.04% | 0.00% | 16,312 | 1,773 | 12.19% | 20,390 | Mar 31, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 400 | 400 | 100.00% | 500 | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 73 | - | - | 91 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.05% | - | 21,590 | - | - | 26,987 | Mar 31, 2024 |
As of Mar 31 2024, Achilles Therapeutics's largest institutional buyer is IKARIAN CAPITAL, LLC. The company purchased 1.44M stocks of ACHL, valued at $1.80M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARTAL GROUP S.A. | 1.88% | 0.02% | 755,375 | -1,500,000 | -66.51% | 944,219 | Mar 31, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | - | - | - | -1,413,809 | -100.00% | - | Mar 31, 2024 |
| BAKER BROS. ADVISORS LP | 3.01% | 0.02% | 1,208,775 | -894,017 | -42.52% | 1,510,969 | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.00% | - | 1,092 | -21,500 | -95.17% | 1,365,000 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.05% | - | 19,117 | -11,832 | -38.23% | 23,896 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.26% | - | 104,993 | -3,461 | -3.19% | 131,241 | Mar 31, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.01% | 0.00% | 2,000 | -1,000 | -33.33% | 2,500,000 | Mar 31, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 137 | -852 | -86.15% | 171 | Mar 31, 2024 |
| SYNCONA PORTFOLIO LTD | 27.59% | 9.24% | 11,086,909 | - | - | 13,858,636 | Mar 31, 2024 |
| FCPM III SERVICES B.V. | 5.95% | 0.42% | 2,390,050 | - | - | 2,987,563 | Mar 31, 2024 |
| REDMILE GROUP, LLC | 4.00% | 0.07% | 1,608,089 | - | - | 2,010,111 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.05% | - | 21,590 | - | - | 26,987 | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 73 | - | - | 91 | Mar 31, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 400 | 400 | 100.00% | 500 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.04% | 0.00% | 16,312 | 1,773 | 12.19% | 20,390 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | 0.01% | - | 3,514 | 3,514 | 100.00% | 4,391,000 | Mar 31, 2024 |
| BRAVE ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,000 | 10,000 | 100.00% | 12,500 | Mar 31, 2024 |
| RESOURCES INVESTMENT ADVISORS, LLC. | 0.03% | 0.00% | 10,500 | 10,500 | 100.00% | 13,125 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.03% | - | 11,799 | 11,799 | 100.00% | 14,749 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.04% | 0.00% | 15,219 | 15,219 | 100.00% | 19,024 | Mar 31, 2024 |
As of Mar 31 2024, Achilles Therapeutics's biggest institutional seller is ARTAL GROUP S.A.. The company sold -1.50M shares of ACHL, valued at $944.22K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IKARIAN CAPITAL, LLC | 3.59% | 0.20% | 1,443,181 | 1,443,181 | 100.00% | 1,803,976 | Mar 31, 2024 |
| STEMPOINT CAPITAL LP | 3.45% | 0.46% | 1,385,750 | 1,385,750 | 100.00% | 1,732,188 | Mar 31, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.05% | 0.01% | 420,481 | 420,481 | 100.00% | 525,601 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.70% | 0.00% | 280,929 | 280,929 | 100.00% | 350,000 | Mar 31, 2024 |
| HRT FINANCIAL LP | 0.09% | 0.00% | 36,918 | 36,918 | 100.00% | 46,000 | Mar 31, 2024 |
| VONTOBEL HOLDING LTD. | 0.05% | 0.00% | 19,000 | 19,000 | 100.00% | 23,750 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 0.04% | 0.00% | 17,900 | 17,900 | 100.00% | 22,375 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.03% | - | 11,799 | 11,799 | 100.00% | 14,749 | Mar 31, 2024 |
| RESOURCES INVESTMENT ADVISORS, LLC. | 0.03% | 0.00% | 10,500 | 10,500 | 100.00% | 13,125 | Mar 31, 2024 |
| BRAVE ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,000 | 10,000 | 100.00% | 12,500 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | 0.01% | - | 3,514 | 3,514 | 100.00% | 4,391,000 | Mar 31, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 400 | 400 | 100.00% | 500 | Mar 31, 2024 |
Achilles Therapeutics's largest new institutional shareholder by number of shares is IKARIAN CAPITAL, LLC, purchased 1.44M shares, valued at $1.80M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| POINT72 ASSET MANAGEMENT, L.P. | - | - | - | -1,413,809 | -100.00% | - | Mar 31, 2024 |
Achilles Therapeutics's largest sold out institutional shareholder by shares sold is POINT72 ASSET MANAGEMENT, L.P., sold -1.41M shares, valued at -, as of undefined.
Achilles Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Collaborative Investment Series Trust | 0.41% | 71,927 | - | - | Dec 31, 2023 |
| ALLSPRING MASTER TRUST | 0.00% | 214,873 | - | - | Feb 29, 2024 |
| LoCorr Investment Trust | 0.00% | 18,782 | - | - | Mar 31, 2024 |
| OPTIMUM FUND TRUST | 0.00% | 40,402 | - | - | Dec 29, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 21,590 | - | - | Feb 29, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 25,934 | - | - | Jan 31, 2024 |
| iSHARES TRUST | 0.00% | 238,114 | - | - | Feb 29, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 39,027 | - | - | Dec 31, 2023 |
| PROSHARES TRUST | 0.00% | 3,293 | - | - | Feb 29, 2024 |
| EMPOWER FUNDS, INC. | 0.00% | 12,361 | - | - | Dec 31, 2023 |
Achilles Therapeutics's largest mutual fund holder by % of total assets is "Collaborative Investment Series Trust", owning 71.93K shares, compromising 0.41% of its total assets.
Achilles Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 14 | -26.32% |
| 31 Dec, 23 | 19 | 11.76% |
| 30 Sep, 23 | 17 | 6.25% |
| 30 Jun, 23 | 16 | 6.67% |
| 31 Mar, 23 | 15 | -25.00% |
| 31 Dec, 22 | 20 | -23.08% |
| 30 Sep, 22 | 26 | 13.04% |
| 30 Jun, 22 | 23 | 4.55% |
| 31 Mar, 22 | 22 | -24.14% |
| 31 Dec, 21 | 29 | 45.00% |
| 30 Sep, 21 | 20 | -31.03% |
| 30 Jun, 21 | 29 | - |
| 31 Mar, 21 | 29 | - |
As of 31 Mar 24, 14 institutions are holding Achilles Therapeutics's shares, representing a decrease of -26.32% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 15,637,900 | -28.21% |
| 31 Dec, 23 | 21,782,170 | 10.61% |
| 30 Sep, 23 | 19,692,035 | -0.48% |
| 30 Jun, 23 | 19,786,405 | -2.15% |
| 31 Mar, 23 | 20,221,841 | -6.60% |
| 31 Dec, 22 | 21,651,848 | -20.60% |
| 30 Sep, 22 | 27,269,868 | 0.50% |
| 30 Jun, 22 | 27,135,177 | 2.13% |
| 31 Mar, 22 | 26,568,801 | -3.15% |
| 31 Dec, 21 | 27,433,848 | 55.90% |
| 30 Sep, 21 | 17,597,157 | -6.32% |
| 30 Jun, 21 | 18,784,796 | 11.77% |
| 31 Mar, 21 | 16,807,348 | - |
Achilles Therapeutics (ACHL) has 15.64M shares outstanding as of 31 Mar 24, down -28.21% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 38.91% | 1.32% |
| 31 Dec, 23 | 54.36% | 2.23% |
| 30 Sep, 23 | 49.35% | 1.99% |
| 30 Jun, 23 | 49.80% | 1.92% |
| 31 Mar, 23 | 50.90% | 1.68% |
| 31 Dec, 22 | 55.07% | 1.14% |
| 30 Sep, 22 | 69.36% | 1.44% |
| 30 Jun, 22 | 69.39% | 1.49% |
| 31 Mar, 22 | 68.31% | 0.75% |
| 31 Dec, 21 | 95.74% | 4.53% |
| 30 Sep, 21 | 45.99% | 1.66% |
| 30 Jun, 21 | 52.64% | 2.37% |
| 31 Mar, 21 | 47.10% | - |
As of 31 Mar 24, Achilles Therapeutics is held by 38.91% institutional shareholders, representing a 1.32% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 8 | - |
| 31 Dec, 23 | 8 | 33.33% |
| 30 Sep, 23 | 6 | 50.00% |
| 30 Jun, 23 | 4 | -33.33% |
| 31 Mar, 23 | 6 | -40.00% |
| 31 Dec, 22 | 10 | -23.08% |
| 30 Sep, 22 | 13 | 44.44% |
| 30 Jun, 22 | 9 | 12.50% |
| 31 Mar, 22 | 8 | -55.56% |
| 31 Dec, 21 | 18 | 200.00% |
| 30 Sep, 21 | 6 | -40.00% |
| 30 Jun, 21 | 10 | -65.52% |
| 31 Mar, 21 | 29 | - |
8 institutional shareholders have increased their position in ACHL stock as of 31 Mar 24 compared to 8 in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 3 | -25.00% |
| 31 Dec, 23 | 4 | - |
| 30 Sep, 23 | 4 | -33.33% |
| 30 Jun, 23 | 6 | 200.00% |
| 31 Mar, 23 | 2 | -60.00% |
| 31 Dec, 22 | 5 | -16.67% |
| 30 Sep, 22 | 6 | - |
| 30 Jun, 22 | 6 | -14.29% |
| 31 Mar, 22 | 7 | 250.00% |
| 31 Dec, 21 | 2 | -50.00% |
| 30 Sep, 21 | 4 | -69.23% |
| 30 Jun, 21 | 13 | - |
| 31 Mar, 21 | - | - |
3 institutional shareholders have reduced their position in ACHL stock as of 31 Mar 24 compared to 4 in the previous quarter (a -25.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 14 | -26.32% | 15,637,900 | -28.21% | 38.91% | 1.32% | 8 | - | 3 | -25.00% |
| 31 Dec, 23 | 19 | 11.76% | 21,782,170 | 10.61% | 54.36% | 2.23% | 8 | 33.33% | 4 | - |
| 30 Sep, 23 | 17 | 6.25% | 19,692,035 | -0.48% | 49.35% | 1.99% | 6 | 50.00% | 4 | -33.33% |
| 30 Jun, 23 | 16 | 6.67% | 19,786,405 | -2.15% | 49.80% | 1.92% | 4 | -33.33% | 6 | 200.00% |
| 31 Mar, 23 | 15 | -25.00% | 20,221,841 | -6.60% | 50.90% | 1.68% | 6 | -40.00% | 2 | -60.00% |
| 31 Dec, 22 | 20 | -23.08% | 21,651,848 | -20.60% | 55.07% | 1.14% | 10 | -23.08% | 5 | -16.67% |
| 30 Sep, 22 | 26 | 13.04% | 27,269,868 | 0.50% | 69.36% | 1.44% | 13 | 44.44% | 6 | - |
| 30 Jun, 22 | 23 | 4.55% | 27,135,177 | 2.13% | 69.39% | 1.49% | 9 | 12.50% | 6 | -14.29% |
| 31 Mar, 22 | 22 | -24.14% | 26,568,801 | -3.15% | 68.31% | 0.75% | 8 | -55.56% | 7 | 250.00% |
| 31 Dec, 21 | 29 | 45.00% | 27,433,848 | 55.90% | 95.74% | 4.53% | 18 | 200.00% | 2 | -50.00% |
| 30 Sep, 21 | 20 | -31.03% | 17,597,157 | -6.32% | 45.99% | 1.66% | 6 | -40.00% | 4 | -69.23% |
| 30 Jun, 21 | 29 | - | 18,784,796 | 11.77% | 52.64% | 2.37% | 10 | -65.52% | 13 | - |
| 31 Mar, 21 | 29 | - | 16,807,348 | - | 47.10% | - | 29 | - | - | - |
ACHL Ownership FAQ
Who Owns Achilles Therapeutics?
Achilles Therapeutics is owned by institutional shareholders (38.91%), insiders (6.51%), and public (54.57%). The largest institutional shareholder of Achilles Therapeutics is SYNCONA PORTFOLIO LTD (27.59% of total shares) and the top mutual fund owner is Collaborative Investment Series Trust (0.41% of total shares).
Who are the major institutional shareholders of Achilles Therapeutics?
Achilles Therapeutics's major institutional shareholders are SYNCONA PORTFOLIO LTD, FCPM III SERVICES B.V., REDMILE GROUP, LLC, VESTAL POINT CAPITAL, LP, and IKARIAN CAPITAL, LLC. The top five shareholders own together 44.86% of the company's share outstanding.
How many Achilles Therapeutics shareholders are there?
As of Mar 2024, there are 14 institutional shareholders of Achilles Therapeutics.
What percentage of Achilles Therapeutics is owned by SYNCONA PORTFOLIO LTD?
SYNCONA PORTFOLIO LTD owns 11.09M shares of Achilles Therapeutics, representing 27.59% of the company's total shares outstanding, valued at $13.86M (as of Mar 2024).
What percentage of Achilles Therapeutics is owned by FCPM III SERVICES B.V?
As of Mar 2024, FCPM III SERVICES B.V holds 2.39M shares of Achilles Therapeutics (ACHL), compromising 5.95% of the company, valued at $2.99M.
What percentage of Achilles Therapeutics is owned by REDMILE GROUP, LLC?
REDMILE GROUP, LLC is the third largest holder of Achilles Therapeutics. The company owns 1.61M of the company's shares outstanding (worth $2.01M).